Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May 7;12(5):dmm035790.
doi: 10.1242/dmm.035790.

Disruption of asxl1 results in myeloproliferative neoplasms in zebrafish

Affiliations

Disruption of asxl1 results in myeloproliferative neoplasms in zebrafish

Evisa Gjini et al. Dis Model Mech. .

Abstract

Somatic loss-of-function mutations of the additional sex combs-like transcriptional regulator 1 (ASXL1) gene are common genetic abnormalities in human myeloid malignancies and induce clonal expansion of mutated hematopoietic stem cells (HSCs). To understand how ASXL1 disruption leads to myeloid cell transformation, we generated asxl1 haploinsufficient and null zebrafish lines using genome-editing technology. Here, we show that homozygous loss of asxl1 leads to apoptosis of newly formed HSCs. Apoptosis occurred via the mitochondrial apoptotic pathway mediated by upregulation of bim and bid Half of the asxl1+/- zebrafish had myeloproliferative neoplasms (MPNs) by 5 months of age. Heterozygous loss of asxl1 combined with heterozygous loss of tet2 led to a more penetrant MPN phenotype, while heterozygous loss of asxl1 combined with complete loss of tet2 led to acute myeloid leukemia (AML). These findings support the use of asxl1+/- zebrafish as a strategy to identify small-molecule drugs to suppress the growth of asxl1 mutant but not wild-type HSCs in individuals with somatically acquired inactivating mutations of ASXL1.

Keywords: Apoptosis; Genome editing; Hematopoietic stem cells; Myeloproliferative neoplasms; Tet2.

PubMed Disclaimer

Conflict of interest statement

Competing interestsK.J. has financial interests in Beam Therapeutics, Editas Medicine, Endcadia, Pairwise Plants, Poseida Therapeutics, and Transposagen Biopharmaceuticals; holds equity in Excelsior Genomics; is a member of the Board of Directors of the American Society of Gene and Cell Therapy; and is a co-inventor on various patents and patent applications that describe gene editing and epigenetic editing technologies. K.J.’s interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies. The other authors have no competing or financial interests to declare.

Figures

Fig. 1.
Fig. 1.
Genome editing with use of transcription activator-like effector nucleases (TALENs) to generate null alleles of the zebrafish asxl1 gene. (A) Site-specific targeting for TALEN-directed Fok1 cleavage within exon 2. (B) Nucleotide sequence alignment of the asxl1Δ10 and asxl1Δ11 zebrafish lines compared to wild-type asxl1. Left, TALEN binding site appears in red; right, TALEN binding site appears in green. Dashes in the DNA sequence represent the nucleotides that are deleted during repair of Fok1-induced DNA double-stranded breaks. (C) Targeted Fok1-induced mutagenic lesions in asxl1 produce frameshift mutations that lead to truncated protein products following short regions of novel amino acids, which are indicated in purple. Red ‘X’ denotes stop codons. (D) The truncated Asxl1 protein products predicted to be expressed in the asxl1Δ10 and asxl1Δ11 mutant lines lack all highly conserved functional domains. Red asterisks denote stop codons. (E) asxl1−/− zebrafish larvae mutants appear shorter in length and slimmer than asxl1+/+ and asxl1+/ zebrafish larvae at day 7 and day 9 post-fertilization. Scale bars: 200 µm. (F) Kaplan–Meier survival curves for asxl1+/+, asxl1+/ and asxl1−/− mutants during the first 35 weeks of life. Asterisk (*) at the base of first curve indicates that ∼8% of asxl1−/− fish grow to normal size and survive.
Fig. 2.
Fig. 2.
Asxl1 loss affects organ development. Histopathological analysis of the muscle, intestine and liver development with hematoxylin and eosin staining in 5 asxl1+/+ and 5 asxl1−/− mutants at 6 dpf and 14 dpf. Muscle (A,D) and intestine (B,E) development had no difference between asxl1+/+ and asxl1−/− embryos at 6 dpf. Liver parenchyma at 6 dpf appeared abnormal with vacuolated cells in asxl1−/− embryos (F) compared with asxl1+/+ embryos (C). At 14 dpf, muscular atrophy was shown in asxl1−/− embryos (J) compared with normal striated muscle in asxl1+/+ embryos (G). Intestine in asxl1−/− embryos was abnormal with villus blunting (K) compared with normal nuclei and microvilli in the asxl1+/+ embryos (H). The asxl1−/− embryos exhibited progressive liver architectural distortion (L) compared to asxl1+/+ embryos (I).
Fig. 3.
Fig. 3.
Loss of asxl1 induces apoptosis in cmyb-expressing embryonic HSPCs. WISH for cmyb was performed at 36 hpf (A) and 3 dpf (B-E) in asxl1+/+, asxl1+/ and asxl1−/− zebrafish embryos. Boxes in panel B are shown at higher magnification in C-E. (F-H) HSPCs (GFP; green) and cells undergoing apoptosis (TUNEL, TMR red, Roche) in the CHT of 48-hpf asxl1+/+, asxl1+/ and asxl1−/− zebrafish embryos in the Tg(cmyb:EGFP) reporter line background were identified by immunofluorescence microscopy following a dual TUNEL/anti-GFP assay. Arrows indicate apoptotic HSPCs with combined EGFP and DMR red fluorescence signals. (I) cmyb:GFP+/TUNEL+ cells in asxl1+/+, asxl1+/− and asxl1−/− were quantified as a percentage of total cmyb:GFP+ cells. Bars represent the mean and s.e.m. for 8-9 embryos each. Unpaired Student’s t-tests and Prism software were used to determine the P-value for each genotypic group compared with control cells.
Fig. 4.
Fig. 4.
Complete loss of asxl1 leads to AML in zebrafish. WISH for cmyb was performed at 3 dpf in asxl1+/+ (A), asxl1+/ (B) and asxl1−/− (C) zebrafish embryos obtained from a cross of two asxl1+/ fish. (D) WISH for cmyb was performed at 3 dpf in asxl1−/− zebrafish embryos obtained from a cross of two asxl1−/− fish. Insets show a higher magnification of the CHT in each panel. (E) MGG staining was performed on kidney marrow smears and peripheral blood smears of asxl1+/+ and asxl1−/− fish at 17 months of age. Normal maturation and morphology are shown across a spread of blood cells in the kidney marrow of the asxl1+/+ zebrafish. In the asxl1−/− fish, the kidney marrow is replaced with immature myeloid blast cells in a pattern resembling AML. Circulating immature myeloid blast cells were observed in the peripheral blood of the asxl1−/− zebrafish, but not asxl1+/+ fish. Erythrocytes, black arrow; myeloid cells, green arrow; blast cells, blue arrow; lymphocytes, red arrow.
Fig. 5.
Fig. 5.
Overexpression of bim and bid mediates apoptosis in asxl1−/− HSPCs. (A,B) Quantitative PCR was performed with cDNA isolated from the trunks of 48 hpf asxl1+/+, asxl1+/ and asxl1−/− zebrafish embryos to quantify the expression of pro-apoptotic (A) and anti-apoptotic (B) members of the Bcl2 family. Expression levels are shown relative to β-actin. The values are means of triplicate runs with s.e.m. Statistical significance was determined with unpaired Student's t-test. Results from a single experiment are shown; however, four independent experiments were performed for both panels A and B with similar results. (C) WISH to detect cmyb with the indicated genotypes at 3 dpf, showing that the loss of HSPCs in asxl1−/− fish is rescued by loss of bim. (D) Cropped CHT regions from panel C were quantified with use of 98 embryos per genotype with ImageJ software. (E) WISH to detect cmyb was performed at 3 dpf for embryos with the indicated genotypes that were injected with 16 ng of either bid morpholino or control morpholino, showing that the loss of HSPCs in asxl1−/− fish is rescued by loss of bid. (F) Cropped CHT regions from panel E were quantified with use of 60 embryos per genotype and ImageJ software. (G) WISH to detect cmyb was performed at 3 dpf for embryos with the indicated genotypes that were injected with 100 ng/µl mRNA encoding either Bcl2 or GFP. Overexpression of bcl2 rescued the loss of HSPCs in asxl1−/− fish. (H) Cropped CHT regions from panel G were quantified with use of 70 embryos per genotype and ImageJ software. In panels D, F and H, black bars representing the median values. Statistical analysis was done with Prism software. Unpaired Student's t-tests were performed in Prism software to determine the P-value for each genotype group compared to controls.
Fig. 6.
Fig. 6.
Combined loss of asxl1 and tet2 leads to MPN and AML in a subset of adult zebrafish. Morphological and quantitative analysis of blood cell types in the kidney marrow and peripheral blood of 5-month-old fish with the indicated genotypes. MGG staining was performed on kidney marrow smears. (A-H) Red arrows denote mature erythrocytes; light blue arrows denote myelomonocytes; green arrows denote lymphocytes; black arrows denote progenitor cells; and orange arrows denote immature red blood cells. (A) In wild-type fish, the kidney marrow hematopoietic cells showed normal maturation and morphology. (B) Five of 11 asxl1+/tet2+/+ fish had an increased number of mature myeloid cells, indicating MPN; the remaining 6 fish had normal morphology. (C) Eight of 11 asxl1+/tet2+/ fish showed an increased number of mature myeloid cells, indicating MPN. (D) Two of 10 asxl1+/tet2−/− fish showed increased myeloid blast cells, indicating AML. Four of the remaining 8 fish had MPN, while the other 4 had normal morphology. (E-H) Analysis of peripheral blood smears by MGG staining. (E) Wild-type fish had normal maturation and morphology of the blood cells. (F) Five of 11 asxl1+/tet2+/+ fish showed rounded circulating immature red blood cells and increased mature myeloid cells. (G) Eight of 11 asxl1+/tet2+/ fish showed immature rounded circulating red blood cells. (H) Two of 10 asxl1+/tet2−/− fish showed an increased number of myeloid blast cells, myelomonocytes and immature erythrocytes. (I-L) Forward- versus side-scatter analysis of kidney marrow cell populations in 5-month-old fish with the indicated genotypes. (M-P) Forward- versus side-scatter analysis of absolute cell numbers per liter of blood in 5-month-old fish with the indicated genotypes, showing increased myelomonocytes and decreased red blood cells in asxl1+/ fish. A subpopulation of asxl1+/tet2−/− fish showed increased progenitor cell numbers in kidney marrow and blood. Mean values with s.e.m. are shown. Statistical analysis was done with Prism software. Unpaired Student's t-tests were performed in Prism to determine the P-value for each genotypic group compared with controls.

References

    1. Abdel-Wahab O., Pardanani A., Patel J., Wadleigh M., Lasho T., Heguy A., Beran M., Gilliland D. G., Levine R. L. and Tefferi A. (2011). Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia 25, 1200-1202. 10.1038/leu.2011.58 - DOI - PMC - PubMed
    1. Abdel-Wahab O., Adli M., LaFave L. M., Gao J., Hricik T., Shih A. H., Pandey S., Patel J. P., Chung Y. R., Koche R. et al. (2012a). ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell 22, 180-193. 10.1016/j.ccr.2012.06.032 - DOI - PMC - PubMed
    1. Abdel-Wahab O., Tefferi A. and Levine R. L. (2012b). Role of TET2 and ASXL1 mutations in the pathogenesis of myeloproliferative neoplasms. Hematol. Oncol. Clin. North Am. 26, 1053-1064. 10.1016/j.hoc.2012.07.006 - DOI - PMC - PubMed
    1. Abdel-Wahab O., Gao J., Adli M., Dey A., Trimarchi T., Chung Y. R., Kuscu C., Hricik T., Ndiaye-Lobry D., Lafave L. M. et al. (2013). Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. J. Exp. Med. 210, 2641-2659. 10.1084/jem.20131141 - DOI - PMC - PubMed
    1. Asada S., Goyama S., Inoue D., Shikata S., Takeda R., Fukushima T., Yonezawa T., Fujino T., Hayashi Y., Kawabata K. C. et al. (2018). Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis. Nat. Commun. 9, 2733 10.1038/s41467-018-05085-9 - DOI - PMC - PubMed

Publication types